June 14, 2011

Alemtuzumab induction in renal transplantation

.   .   

Alemtuzumab is a monoclonal antibody developed for treatment of lymphoma that profoundly depletes both T- and B-cells, and has been used off-label in transplantation. This randomized controlled trial compared alemtuzumab to induction with either thymoglobulin or basiliximab, and with rapid corticosteroid withdrawal. There were fewer acute rejections at one year with alemtuzumab compared to conventional therapy, chiefly due to a difference in rejection rates between patients receiving alemtuzumab compared to basiliximab. Of note, at three years there was no difference in acute rejection rates due to more late rejections in the alemtuzumab group, and patient and graft survival were similar.

Related Articles:

Renal Transplantation

Comments are closed.